New drug A3907 tested for rare liver disease, study halted early
Disease control
Terminated
This study tested a drug called A3907 in 18 adults with Primary Sclerosing Cholangitis (PSC), a rare liver disease. The goal was to check if the drug is safe and how the body processes it. The study was stopped early, so results are limited.
Phase: PHASE2 • Sponsor: Albireo, an Ipsen Company • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC